New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its business show that will air as a sponsored program on Bloomberg TV tonight, Thursday, March 7, 2024, at 9:30 PM PT.

New to The Street's TV episode 560 will air the following five (5) business interviews:

1)."Game Changers" segment interview with PetVivo Holdings, Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) John Lai, CEO/President.

2). Biopharmaceutical - Tonix Pharmaceuticals, Inc.'s euticals, Inc.'s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, Chairman and CEO.

3). Sustainable Solutions - VRM BioLogik® Group's (VRM) interview with Ken Bellamy, Founder and President.

4). Financial Marketplace Strategies – Blue Castle Ventures LTD's ($BCVD) interviews with David Rojas, CEO/Founder.

5). "Sekur Privacy & Sekur Security – Weekly Hack” segment with internet privacy expert Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®).

Episode 560

New to The Street airs its "Game Changers" segment with TV Host and Multi-media Journalist Ana Berry, who talks with John Lai, CEO/President of PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) ("PetVivo"). With creative therapeutic medical innovations for pets, PETV is a "Game Changer." Owners of dogs, cats, and horses are seeing remarkable results when using the Company's SPRYNG™ with OsteoCushion Technology ("SPRYNG™"), an intra-articular injectable veterinary medical device consisting of cellular matrix microparticles. Veterinarians are increasingly using the product as an alternative to surgery, helping pet owners manage pets with osteoarthritis and other joint-related ailments. John goes over three corporate milestones. First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease. The next milestone was the Company's ability to attract Covetrus North America, LLC, another largest veterinarian medical distributor; now, the three largest medical distributors carry SPRYNG™. In January 2024, the third milestone veterinarian doctors who were keynote speakers at the Veterinary Meeting & Expo (VMX) conference in Orlando, Florida, endorsing their successful use of the Company's SPRYNG™ product in small animal cases. Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses. The Company expects sales increases for product uses for small pets, dogs, and cats, as these recent studies, presentations, and distributors are educating pet owners and vets about SPRYNG™ positive treatment outcomes. The Company has five more pending studies, with expected results reported before the conclusion of 2024. PETV's SPRYNG™ with OsteoCushion Technology is a "Game Changer" medical device that successfully treats pets and gives owners options beyond surgeries. The on-screen QR code is available during the show; download or visit PetVivo Holdings, Inc. - & Spryng with OsteoCushion Technology -

From the Nasdaq MarketSite Studio, Dr. Seth Lederman, MD, Chairman and CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) ("Tonix"), talks with New to The Street's TV Host Jane King about the Company's successful completion of Phase 3 studies on its fibromyalgia drug. Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia. The drug is a non-opioid, non-addictive painkiller. Since 2009, there have been no new fibromyalgia drugs available in the marketplace. Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in treatment success. Competitor drugs cause sleeplessness and low energy. Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish patient fatigue. The side effects are minimal, with around 3% of patients experiencing headaches and some drowsiness. Administered as a sublingual tablet, Tonmya™ has caused tongue numbness in a few patients. Patients take the drug at bedtime, which can block brain signals that are often associated with pain, and the drug has shown improved sexual functionality. Dr. Lederman expects the Company to submit its full report to the FDA for market approval sometime during the first half of 2024, with a full approval expectation sometime in 2025. The on-screen QR code is available during the shows; download or visit Tonix Pharmaceuticals, Inc. -

New to The Street airs TV Host Jane King's interview with VRM BioLogik® Group's (VRM) Ken Bellamy, Founder and President. As a leading technology company utilizing microbial formulations, VRM is creating solutions for significant organic waste mitigation and recycling issues facing the planet. Ken explains that using organic catalysts and waste materials, the Company develops technologies that improve soils, increasing agricultural productivity and water conservation. VRM offers solutions to small growers and large governmental organizations to recycle organic waste into usable nutrient-rich products. Ken talks about VRM's participation in the COP 28 event in Dubai, where they showcased innovative solutions and case studies. VRM had the privilege of delivering a speech on behalf of the Government of Indonesia at the event, emphasizing the government's six years of experience and initiatives using VRM's innovative, environmentally sound technologies, products, and services. Currently, VRM is working with nine other countries seeking environmentally sound solutions to significantly improve waste management conversion into functional products. Global private and public entities are increasingly looking to improve crop yields and increase available agricultural acreage to eliminate food insecurities. VRM continues to find innovative technologies that can assist and repair the planet's ecosystem. The on-screen QR code is available during the show; download or visit VRM BioLogik® Group -

New to The Street's TV Host Joya Dass from the Nasdaq MarketSite Studio talks with David Rojas, Chief Executive Officer/Founder of Blue Castle Ventures, Ltd.'s ($BCVD) ("Blue Castle"). As a financial marketplace and educational platform, Blue Castle continues to grow its customer base. With clients in Canada, Mexico, Ecuador, and other South American countries. The Company is proceeding to enter the U.S. market. David explains that the Company continues to proceed with all the necessary regulatory approvals for product offerings to U.S. customers. Blue Castles' clients have seen great success utilizing the Company's resources with its asset-backed financial products, financial educational training courses, digital art marketing, and other services. Clients become "Club Members," paying a one-time fee to access all the unique financial services, educational tools, and digital art auctions. Last year, Blue Castle did a digital art auction, utilizing NFTs backed by the physical assets of the artwork. Both clients and artists can access new markets and collect unique works of art while utilizing a blockchain to ensure transparency and collectability. David explains that Blue Castle can offer its products to anyone and will not limit services based on portfolio values. Conventional financial servicing models will limit client access based on portfolio size and trading experiences. Blue Castle's disruptive financial products rival conventional legacy financial products; clients are getting great returns on Blue Castle's investment products and strategies. Concurrently, clients receive educational training to understand financial markets better. Blue Castle Ventures, Ltd. does not trade cryptocurrencies nor carry out transactions or investments with cryptocurrencies. All the Company's operations are in U.S. dollars. The Company's blockchain, $BCVD, is a cryptography and security system. The on-screen QR code is available during the show; download or visit Blue Castle Ventures, Ltd. -

New to The Street T.V. airs its "Sekur Privacy & Sekur Security Segment – The Weekly Hack" with internationally acclaimed internet privacy expert Alain Ghiai, CEO of Sekur Private Data Ltd.  (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF). TV Host and Multi-media Journalist Ana Berry and Alain discuss a recent report from the FBI about Chinese operatives cyberattacking America's energy grid and other critical infrastructure. The FBI warning about grid attacks is nothing new; it appears that in each federal election cycle, foreign entities try to hack governmental and corporate databases as a form of election interference and for other nefarious reasons. Business Emal Compromise (BEC) is a problem; 91% of hacks are from compromised email accounts. Alain says that businesses and individuals can limit a possible cybersecurity problem by reducing social media posts. Typically, a hacker follows a social media post, finds weaknesses in a poster's internet platform, and then exploits those weaknesses. A hacker usually monitors email accounts for specific and personal information to hack. They might watch emails for weeks, collecting sensitive data long before committing data theft. Sekur offers businesses, individuals, and governmental entities affordable encrypted solutions to fend off possible email compromises. SekurVPN, SekurMail, and SekurMessenger subscription services provide military-grade encryption with easy-to-use features, giving end-users private and secure electronic communications. Many subscribers are realizing the benefits of bundling subscriptions with the Company's SekurVPN services, which operate on multiple Sekur servers owned and located in Switzerland, a country with very tough privacy laws. Under Swiss law, your IP address is private property protected under Swiss laws. The Company never tracks your devices, never sells data, doesn't use 3rd party platforms, never asks for phone numbers, and keeps one's internet traffic private and secure. PROMO CODE: PRIVACY is now available, giving 15% savings toward monthly and yearly subscriptions, and the discount will remain active for five years. Viewers, please tune in next time for the newest cybersecurity topic on the "Sekur Privacy & Sekur Security– Weekly Hack" segment. The on-screen QR. code is available during the shows to download more info or visit Sekur Private Data, Ltd., http:/ and Privacy has arrived!

About PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV):

PetVivo Holdings Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for treating companion animals in a capital and time-efficient way. A vital component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics. PetVivo has a robust pipeline of products for treating animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes, and use methods. The Company's lead product, SPRYNG with OsteoCushion technology, a veterinarian-administered, intra-articular injection for the Management of lameness and other joint-related afflictions, including osteoarthritis in cats, dogs, and horses, is currently available for commercial sale -

About Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP):

Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) ("Tonix") is a biopharmaceutical company focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system disorders. Tonix's priority is to submit a New Drug Application (NDA) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to reduce the severity of acute stress reactions and the frequency of acute stress disorder and post-traumatic stress disorder. This trial is being sponsored by the University of North Carolina and received funding support from the U.S. Department of Defense. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and top-line results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA and received funding from the National Institute on Drug Abuse (NIDA). A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix's rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (PWS). The FDA has granted TNX-2900 Orphan Drug designation, and an investigational new drug (IND) application has been cleared to support a Phase 2 study in PWS patients. Tonix's immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 was initiated in the third quarter of 2023. Tonix's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, which is being developed as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID) Project NextGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small-molecule oral antivirals. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC, from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. (*Tonix's product development candidates are investigational new drugs or biologics and have not been approved for any indication; Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.) -

About VRM Biologik:

VRM Biologik is a renowned biotech intellectual property development leader committed to revolutionizing various industries through innovative solutions. With a strong background in research and development, VRM Biologik aims to create sustainable and transformative products that address pressing global challenges. Their sustainable technologies are designed to address environmental challenges and promote a more sustainable future –

About Blue Castle Ventures, LTD. ($BCVD):

Blue Castle Ventures, LTD. ($BCVD) provides clients in Canada and several countries globally the opportunity to access global markets with actively managed strategies that take advantage of the latest asset trends. The Company aims to level the playfield by bringing the same advantages and opportunities that high-net-worth individuals have to retail investors and reducing their exposure to the volatility and potential losses that a lack of knowledge of modern trends can cause. For four years, Blue Castle Ventures LTD has successfully designed strategies for momentum trading in stocks to the point that it grew almost three times during the pandemic, which has now allowed the Company to debut in the digital assets world. The Company has launched its own blockchain system capable of exchanging a Point Program, "Blue Castle Ventures Dollar" or "BCVD," and the bartering of "Digital Art" directly to USD dollars. The operation relies on regulated financial institutions in Canada and the U.S. These institutions provide The Company with banking, trading, payment, and brokerage services, which allow them to provide customers with the safest and most efficient approach -

About Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF):

Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) is a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure communications and secure data management. The Company distributes a suite of secure cloud-based storage, disaster recovery, document management, encrypted emails, and secure communication tools. It sells its products through its websites,, approved distributors, and telecommunication companies worldwide. Sekur Private Data, Ltd. serves consumers, businesses, and governments worldwide - https:/ and; Twitter: @sekurprivate.

About New to The Street:

New to The Street is an FMW Media production that operates one of the longest-running U.S. and International sponsored and syndicated Nielsen-rated programming television brands, "New to The Street." Since 2009, New to The Street has run biographical interview segment shows across major U.S. television networks. The Nielsen-rated and sponsored broadcast programming platform reaches millions of homes in the U.S. and international markets. FMW's New to The Street show appears on Bloomberg and the FOX Business Network as sponsored programming. FMW is also one of the nation's largest buyers of linear television, long and short-form paid programming -

Forward-Looking Statements Disclaimer U.S./Canada:

This press release contains forward-looking statements within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. Forward-looking statements do not guarantee future performance or results and will not necessarily be accurate indications of when such performance or results are achieved. This press release should be considered in all filings of the Companies contained in the Edgar Archives of the Securities and Exchange Commission at

This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as "seek," "anticipate," "believe," "plan," "estimate," "expect," "likely," and "intend" and statements that an event or result "may," "will," "should," "could" or "might" occur or be achieved and other similar expressions. These statements reflect Management's current beliefs and are based on information currently available to Management as of the date hereof. Forward-looking information in this press release includes, without limiting, the foregoing expectations. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


FMW Media Contact:
Monica Brennan

"New to The Street" Business Development Office

A photo accompanying this announcement is available at